These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 6220187)

  • 1. Dynamic membrane studies in individuals at risk for Huntington's disease.
    Pettegrew JW; Minshew NJ; Stewart RM
    Life Sci; 1983 Mar; 32(11):1207-12. PubMed ID: 6220187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membrane studies in Huntington's disease: steady state and time-dependent fluorescence spectroscopy of intact lymphocytes.
    Pettegrew JW; Nichols JS; Stewart RM
    J Neurochem; 1981 Jun; 36(6):1966-76. PubMed ID: 6453955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane studies in Huntington's disease: steady-state fluorescence studies of intact erythrocytes.
    Pettegrew JW; Nichols JS; Stewart RM
    Ann Neurol; 1980 Oct; 8(4):381-6. PubMed ID: 6449174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric detection of lymphocyte alterations in Huntington's disease.
    Gollin SM; Leary JF; Shoulson I; Doherty RA
    Life Sci; 1985 Feb; 36(7):619-26. PubMed ID: 2857470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitivity in Huntington's disease: implications for pathogenesis and presymptomatic diagnosis.
    Moshell AN; Tarone RE; Barrett SF; Robbins JH
    Lancet; 1980 Jan; 1(8158):9-11. PubMed ID: 6101401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huntington's disease like-2: review and update.
    Margolis RL; Rudnicki DD; Holmes SE
    Acta Neurol Taiwan; 2005 Mar; 14(1):1-8. PubMed ID: 15835282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Huntington's disease: abnormality of lymphocyte capping.
    Noronha AB; Roos RP; Antel JP; Arnason BG
    Ann Neurol; 1979 Nov; 6(5):447-50. PubMed ID: 160212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a community-based exercise program for people diagnosed and at-risk for Huntington's disease: A clinical report.
    Clark D; Danzl MM; Ulanowski E
    Physiother Theory Pract; 2016; 32(3):232-9. PubMed ID: 27046737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genetic study of red cell osmotic fragility in Huntington's disease.
    McCormack MK; Lazzarini A; Toke D; Lepore F
    Am J Med Genet; 1984 May; 18(1):5-11. PubMed ID: 6234801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of the Huntington's Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs.
    Simpson JA; Lovecky D; Kogan J; Vetter LA; Yohrling GJ
    J Huntingtons Dis; 2016 Dec; 5(4):395-403. PubMed ID: 27983566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.
    Borovecki F; Lovrecic L; Zhou J; Jeong H; Then F; Rosas HD; Hersch SM; Hogarth P; Bouzou B; Jensen RV; Krainc D
    Proc Natl Acad Sci U S A; 2005 Aug; 102(31):11023-8. PubMed ID: 16043692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin sensitivity and early-phase insulin secretion in normoglycemic Huntington's disease patients.
    Russo CV; Salvatore E; Saccà F; Tucci T; Rinaldi C; Sorrentino P; Massarelli M; Rossi F; Savastano S; Di Maio L; Filla A; Colao A; De Michele G
    J Huntingtons Dis; 2013; 2(4):501-7. PubMed ID: 25062734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.
    Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K
    J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane anomalies in Huntington's disease fibroblasts.
    Schroeder F; Goetz IE; Roberts E
    J Neurochem; 1984 Aug; 43(2):526-39. PubMed ID: 6330302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating microRNAs in Huntington's disease: Emerging mediators in metabolic impairment.
    Díez-Planelles C; Sánchez-Lozano P; Crespo MC; Gil-Zamorano J; Ribacoba R; González N; Suárez E; Martínez-Descals A; Martínez-Camblor P; Álvarez V; Martín-Hernández R; Huerta-Ruíz I; González-García I; Cosgaya JM; Visioli F; Dávalos A; Iglesias-Gutiérrez E; Tomás-Zapico C
    Pharmacol Res; 2016 Jun; 108():102-110. PubMed ID: 27155059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic disturbances in plasma as biomarkers for Huntington's disease.
    Cheng ML; Chang KH; Wu YR; Chen CM
    J Nutr Biochem; 2016 May; 31():38-44. PubMed ID: 27133422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for normal fibroblast cell membranes from individuals with Huntington's disease. A fluorescence probe study.
    Sumbilla C; Lakowicz JR
    J Neurol Sci; 1983 Dec; 62(1-3):23-40. PubMed ID: 6230415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Huntington's disease: trinucleotide disease or polyglutamine disease?].
    Ide K; Nukina N; Kanazawa I
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1540-1. PubMed ID: 8752457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients.
    Almeida S; Sarmento-Ribeiro AB; Januário C; Rego AC; Oliveira CR
    Biochem Biophys Res Commun; 2008 Oct; 374(4):599-603. PubMed ID: 18625199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex and age alter plasma membranes of cultured fibroblasts.
    Schroeder F; Goetz I; Roberts E
    Eur J Biochem; 1984 Jul; 142(1):183-91. PubMed ID: 6086340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.